Encouraging News from Cassava Sciences

Cassava Sciences Announces Top-Line Clinical Data for Simulfilam
Cassava Sciences Press Release Today
Cassava Sciences (SAVA) announced top-line clinical data today from a pre-planned interim analysis of an on-going open-label study with its drug candidate simufilam in patients with mild-to-moderate Alzheimer’s disease.

In a study funded by the National Institutes of Health (NIH), ADAS-Cog11 . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.